Hunter syndrome therapeutics market seen reaching $1.78 billion by 2030

The global market for Hunter syndrome therapies is projected to grow from $1.24 billion in 2025 to $1.78 billion by 2030, driven by enzyme replacement therapy, gene therapy development and broader newborn screening. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Hunter syndrome is a rare genetic disorder with limited treatment options, so market growth reflects both unmet medical need and rising investment in orphan drugs. - Stronger demand could accelerate enzyme replacement therapy, gene therapy and earlier diagnosis for patients with mucopolysaccharidosis II.

What happened: - The Business Research Company published its Hunter Syndrome Therapeutics Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the market will rise from $1.24 billion in 2025 to $1.33 billion in 2026. - The report projects the market will reach $1.78 billion by 2030, implying a 7.6% compound annual growth rate over the forecast period. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample is available here. - The full report is available here.

The details: - Hunter syndrome therapeutics are treatments for mucopolysaccharidosis II, a rare X-linked condition caused by deficiency of the enzyme iduronate-2-sulfatase. - The therapies aim to slow disease progression, reduce symptoms and improve quality of life by addressing the biochemical imbalance at the molecular level. - The report links historic growth to better access to enzyme replacement therapies, greater awareness of lysosomal storage disorders, orphan-drug incentives, higher rare-disease research funding and improved access to specialty treatment centers. - The forecast is supported by gene therapy platforms designed for Hunter syndrome, wider use of precision medicine, broader newborn screening, a growing pipeline of candidates and deeper biotech-research collaborations. - Expected trends include continued use of enzyme replacement therapy for long-term management, clinical progress in gene therapies, more early detection through newborn screening, more personalized treatment by disease severity and higher investment in rare disease research. - The report also highlights rising healthcare investment in rare diseases as a key growth driver. - Rare disorders affect fewer than 1 in 2,000 people and often face limited treatment choices, which has encouraged government support through orphan-drug policies, tax incentives and regulatory frameworks. - Global Genes reported that rare disease drug developers raised $7.1 billion in the first quarter of 2024 through public equity and debt financing, up 307% from $1.8 billion in the same period of 2023.

Between the lines: - The growth forecast suggests Hunter syndrome is moving from a niche therapy area toward a more structured rare-disease commercial market. - The strongest upside likely sits with platforms that combine earlier diagnosis, precision treatment and long-term disease management. - The fundraising surge in rare diseases points to a broader capital market appetite for orphan-drug development, not just Hunter syndrome.

What's next: - The market will likely be shaped by progress in gene therapy, regulatory support for orphan drugs and expansion of newborn screening programs. - Asia-Pacific’s growth rate will be a key signal for where future commercial and research activity may concentrate. - The report points to continued investment in rare-disease therapeutics and clinical development through 2030.

The bottom line: - Hunter syndrome therapeutics has a growing market, and the next phase of expansion is likely to come from gene therapy, earlier diagnosis and broader rare-disease investment.